DGAP-News

Biotest AG: Biotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections - Seite 2

In addition to this, with trimodulin Biotest is developing a polyvalent antibody preparation to combat COVID-19, as well as a COVID-19 hyper immunoglobulin as part of a plasma alliance cooperation. Biotest is therefore pursuing a number of promising approaches aimed at providing critically ill COVID-19 patients with further effective treatment options as quickly as possible by means of accelerated approval procedures.

About Pentaglobin^(R)
Pentaglobin^(R) is the first and only IgM-enriched immunoglobulin preparation for intravenous use. Pentaglobin^(R) significantly increases the survival rate of patients with severe bacterial infections and acts against a broad spectrum of bacterial pathogens. Pentaglobin's^(R) acts anti-bacterial by fast neutralization of bacterial endo- and exotoxins and anti-inflammatory by scavenging excessively activated complement factors. Pentaglobin^(R) is licensed in several countries for the treatment of severe bacterial infections in combination with antibiotics.

About COVID-19
COVID-19 is a respiratory disease caused by the novel severe acute respiratory syndrome corona virus 2 variant (SARS-CoV-2). While most cases are mild or asymptomatic, COVID-19 patients may present at the hospital with typical signs of pneumonia requiring oxygen support. This disease stage is regularly accompanied by an excessive immune response and can lead to systemic inflammation reactions. Furthermore, patients may progress to critical disease with need for intensive care, including invasive mechanical ventilation. This clinical picture and course of the disease resembles that of severe community acquired pneumonia (sCAP) caused by other pathogens.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.